SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally

Photo © iStockphoto.com/Tina_Rencelj

SourceOne Global Partners (Chicago, IL) has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace. AlmegaPL uses a proprietary strain of photoautotrophic microalgae Nannochloropsis rich in eicosapentaenoic acid (EPA) that has been shown to in research to lower cholesterol levels in healthy subjects.^1,2 The ingredient has also been subject to a successful new dietary ingredient notification with the U.S. Food and Drug Administration (FDA), and has been cleared as a medicine in Australia by the country’s Therapeutic Goods Agency (TGA).

“Forming partnerships with ingredient manufacturers who deeply value innovation, intellectual property, and robust supporting science remains SourceOne’s priority. This commitment underscores our dedication to our global network of brand partners and contract manufacturers that we’ve built over the past 21 years,” said Jesse Lopez, CEO and founder of SourceOne, in a press release. “Our new partnership with Qualitas Health marks a significant milestone in the omega-3 industry, allowing us to offer our valued customers substantial differentiation through patented and clinically proven AlmegaPL solutions across a broad range of product applications.”

“SourceOne has an unrivaled reputation for its sales and marketing expertise of innovative ingredients and life science technologies,” said Tom Dimke, CEO of Qualitas Health. “With a global distribution infrastructure and an unmatched technology partner exchange that adds value to AlmegaPL ingredients, SourceOne is the perfect partner to exclusively represent the Qualitas Health algae-based omega-3 portfolio to leading brands around the world.”

According to Qualitas Health, the unique lipid structure and emulsion properties of its AlmegaPL offer 1.7 times better absorption into the bloodstream, and the partnership with SourceOne will give customers access to the microalgae ingredient formulated with SourceOne’s VESIsorb drug delivery system.³ SourceOne states that the delivery system improves AUC of omega-3 fatty acids by 26-fold, based on pharmacokinetic research.

References

1. Rao, A.; Briskey, D.; Nalley, J.O.; Ganuza, E. Omega-3 Eicosapentaenoic Acid (EPA) Rich Extract from the Microalga Nannochloropsis Decreases Cholesterol in Healthy Individuals: A Double-Blind, Randomized, Placebo-Controlled, Three-Month Supplementation Study. Nutrients. 2020, 12 (6), 1869. DOI: 10.3390/nu12061869
2. Ganuza, E.; Etomi, E.H.; Olson, M.; Whisner, C.M. Omega-3 eicosapentaenoic polar-lipid rich extract from microalgae Nannochloropsis decreases plasma triglycerides and cholesterol in a real-world normolipidemic supplement consumer population. Front. Nutr. 2024, 11. DOI: 10.3389/fnut.2024.1293909
3. Kagan, M.L.; West, A.L.; Zante, C.; Calder, P.C. Acute appearance of fatty acids in human plasma – a comparative study between polar-lipid rich oil from the microalgae Nannochloropsis oculata and krill oil in healthy young males. Lipids Health Dis. 2013, 12, 102. DOI: 10.1186/1476-511X-12-102